Outpatient thyroid remnant ablation using repeated low 131-iodine activities (740 MBq/20 mCi x 2) in patients with low-risk differentiated thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 3, 2012, Pages 871-880

  Clerc, Jérôme ^a   Bienvenu Perrard, Marie ^a   Pichard De Malleray, Caroline ^a   Dagousset, Franco̧ise ^a   Delbot, Thierry ^a   Dreyfuss, Marc ^a   Groussin, Lionel ^a   Marlowe, Robert J ^b   Leger, Franco̧ise Aubeǹe ^a   Chevalier, Alain ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Spencer Fontayne Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LIOTHYRONINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROXINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIATED THYROID CANCER; DOPPLER ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTPATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROID REMNANT ABLATION; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84858009789     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1882     Document Type: Article

References (30)

1. Mazzaferri EL 2009 What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)? Oncology 23:579-588
2. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Sturgeon C 2007 Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246:375-381; discussion 381-384
3. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW 2009 Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 94:4171-4179
4. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
5. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A 2002 Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063-4068
6. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Turco A, Mariani G 2006 Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun 27:627-632 (Pubitemid 44305303)
7. Bal CS, Kumar A, Pant GS 2004 Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 89:1666-1673 (Pubitemid 38507919)
8. Mäenpää HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H 2008 Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS ONE 3:e1885
9. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS 2010 Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 20:173-179
10. Chianelli M, Todino V, Graziano FM, Panunzi C, Pace D, Guglielmi R, Signore A, Papini E 2009 Low-activity (2.0 GBq; 54 mCi) radio-iodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 160:431-436
11. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Cipri C, Pacini F 2007 A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542-3546 (Pubitemid 47435333)
12. Rosario PW, Xavier AC 3 February 2011 Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients. Am J Clin Oncol 10.1097/COC.0b013e318201a41a
13. Catargi B, Borget I, Deandris D, Zerdoud S, Bridji B, Bardet S, Rousseau A, Bastie D, Schvartz C, Vera P, Morel O, Benivsy D, Bournaud C, Bonichon F, Dejax C, Toubert ME, Benhamou E, Schlumberger M, Comparison of four strategies of radioiodine ablation in patients with thyroid cancer with low-risk of recurrence: the randomized prospective ESTIMABL study on 573 patients. International Thyroid Congress, Paris, France, 2010 (Abstract P-1665)
14. Mallick U, Harmer C, Clarke S, Moss L, Nicol A, Clarke P, Smellie J, McCready R, Farnell K, Franklyn J, John R, Nutting C, Yap B, Lemon C, Wadlsey J, Gerrard G, Roques T, Macias E, Whitaker S, Abdul-Hamid A, Alvarez P, Kadalayil L, Hackshaw A, HiLo: Multicentre randomised phase III clinical trial of high vs low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation for differentiated thyroid cancer. International Thyroid Congress, Paris, France, 2010 (Abstract OC-068)
15. Fleming I, Cooper, JS, Henson, DE, Hutter, RVP, Kennedy, BJ 1997 AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott- Raven
16. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648-654 (Pubitemid 46768466)
17. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F 2008 BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93:3943-3949
18. Leger FA, Izembart M, Dagousset F, Barritault L, Baillet G, Chevalier A, Clerc J 1998 Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 25:242-246 (Pubitemid 28181723)
19. Czepczyñski R, Ziemnicka K, Baczyk M, Oleksa R, Ruchała M, Sowiñski J 2005 Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma. Thyroid 15:1261-1265 (Pubitemid 41821760)
20. Hung GU, Tu ST, Wu IS, Yang KT 2004 Comparison of the effec- tiveness between a single low dose and fractionated doses of radioiodine in ablation of post-operative thyroid remnants. Jpn J Clin Oncol 34:469-471
21. Wu HS, Hseu HH, Lin WY, Wang SJ, Liu YC 2005 Decreased uptake after fractionated ablative doses of iodine-131. Eur J Nucl Med Mol Imaging 32:167-173
22. Löffler M, Weckesser M, Franzius C, Kies P, Schober O 2003 Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuklearmedizin 42:240-243 (Pubitemid 38101132)
23. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932 (Pubitemid 43357760)
24. Tala Jury HP, Castagna MG, Fioravanti C, Cipri C, Brianzoni E, Pacini F 2010 Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab 95:230-237
25. Vaiano A, Claudio Traino A, Boni G, Grosso M, Lazzeri P, Colato C, Davì MV, Francia G, Lazzeri M, Mariani G, Ferdeghini M 2007 Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh- TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal. Nucl Med Commun 28:215-223 (Pubitemid 46192957)
26. Taïeb D, Sebag F, Farman-Ara B, Portal T, Baumstarck-Barrau K, Fortanier C, Bourrelly M, Mancini J, DeMicco C, Auquier P, Conte-Devolx B, Henry JF, Mundler O 2010 Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. J Clin Endocrinol Metab 95:3283-3290
27. 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Exp Clin Endocrinol Diabetes 118:393-399
28. Schlumberger M, Borget I, Nascimento C, Brassard M, Leboulleux S 2011 Treatment and follow-up of low-risk patients with thyroid cancer. Nat Rev Endocrinol 7:625-628
29. Stajduhar KI, Neithercut J, Chu E, Pham P, Rohde J, Sicotte A, Young K 2000 Thyroid cancer: patients' experiences of receiving iodine-131 therapy. Oncol Nurs Forum 27:1213-1218
30. Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scélo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, McBride ML, Kee-Seng C, Pompe-Kirn V, Kliewer EV, Tonita JM, Jonasson JG, Martos C, Boffetta P, Brennan P 2006 Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 91:1819-1825